Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus
NCT04615013Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2020
- Primary completion
- Oct 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NBTXR3 in esophageal adenocarcinoma (EAC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of dose limiting toxicities at Day 85 and Maximum tolerated dose and recommended phase 2 dose at Day 85. Started Nov 2020; status: recruiting.
02
Drugs
NBTXR3
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT04615013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615013.